Handelsbanken Fonder AB Acquires 8,486 Shares of Insulet Corporation $PODD

Handelsbanken Fonder AB increased its holdings in Insulet Corporation (NASDAQ:PODD) by 40.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 29,502 shares of the medical instruments supplier’s stock after purchasing an additional 8,486 shares during the period. Handelsbanken Fonder AB’s holdings in Insulet were worth $8,386,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PODD. Elyxium Wealth LLC acquired a new stake in Insulet during the 4th quarter worth about $28,000. Whittier Trust Co. of Nevada Inc. grew its holdings in Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 43 shares during the period. Measured Wealth Private Client Group LLC acquired a new stake in Insulet during the 3rd quarter worth about $49,000. Osterweis Capital Management Inc. acquired a new stake in Insulet during the 2nd quarter worth about $51,000. Finally, Zions Bancorporation National Association UT grew its holdings in Insulet by 57.3% during the 3rd quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 63 shares during the period.

Insulet Trading Up 0.2%

PODD opened at $156.89 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a fifty-two week low of $145.59 and a fifty-two week high of $354.88. The firm has a market capitalization of $10.87 billion, a PE ratio of 36.49, a P/E/G ratio of 1.24 and a beta of 1.20. The company’s 50-day moving average is $193.21 and its 200 day moving average is $251.96.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter in the prior year, the business posted $1.02 EPS. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts predict that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PODD. Barclays decreased their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Weiss Ratings downgraded Insulet from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 15th. The Goldman Sachs Group set a $237.00 price target on Insulet in a report on Thursday, May 7th. Piper Sandler decreased their price target on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Finally, Jefferies Financial Group decreased their price target on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $254.96.

Insider Buying and Selling

In other news, Director Michael R. Minogue acquired 2,030 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.36% of the company’s stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.